Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin vs Best Supportive Care in Advanced Soft Tissue Sarcoma
NCT02672527Phase 3Completed
- Sponsor
- Gustave Roussy
- Start
- Jan 2015
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Trabectedin with Best Supportive Care (2 arms). Primary endpoint: Progression-Free Survival at 30 months. Started Jan 2015; status: completed.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02672527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02672527.